Literature DB >> 19921579

[Clinicopathological significance of microRNA-21 and miR-125 expression in colorectal cancer].

Yi Zhang1, Zong-guang Zhou, Ling Wang, Peng Zhang, Mo-jin Wang, Chang-fu Cui, Jian-ting Guan, Ke-ling Chen, Lan Zhan.   

Abstract

OBJECTIVE: To investigate the expression of microRNA(miR)-21 and miR-125 in colorectal cancer (CRC) and its relationship with clinicopathological features.
METHODS: Quantitative real-time PCR was applied to examine the expression of miR-21 and miR-125 in 100 primary CRC specimens which were diagnosed and operated in West China Hospital between 2006 and 2007, in comparison with the corresponding normal mucosa specimens. The relationship between the expression of miRNAs and clinicopathological features was analyzed.
RESULTS: The expression of miR-21 in CRC was up-regulated by 2.3 times compared to normal mucosa (P =0.025), while the expression of miR-125 was down-regulated by 3.3 times in comparison with normal mucosa (P =0.005). Furthermore, the expression of miR-21 was related to TNM stage (P =0.028) and local invasion (P =0.023). On the other hand, no significant relationship was found between the expression of miR-125 and clinicopathological features (P >0.05).
CONCLUSION: The over-expression of miR-21 may play a role in the development and progression of CRC, while miR-125 may not be related to the pathogenesis of CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19921579

Source DB:  PubMed          Journal:  Zhonghua Wei Chang Wai Ke Za Zhi        ISSN: 1671-0274


  2 in total

Review 1.  mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer.

Authors:  Karen Griselda de la Cruz López; Mariel Esperanza Toledo Guzmán; Elizabeth Ortiz Sánchez; Alejandro García Carrancá
Journal:  Front Oncol       Date:  2019-12-13       Impact factor: 6.244

2.  microRNA-208a in an early stage myocardial infarction rat model and the effect on cAMP-PKA signaling pathway.

Authors:  Gao Feng; Zhang Yan; Chuanchuan Li; Yuemei Hou
Journal:  Mol Med Rep       Date:  2016-06-14       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.